Vascular inflammation and the renin-angiotensin system

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 8, 2002, Pages 1257-1266

  Brasier, Allan R ^a,b   Recinos III, Adrian ^a   Eledrisi, Mohsen S ^a   Runge, Marschall S ^c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c NONE

Author keywords

Angiotensin II; Angiotensinogen; Atherosclerosis; Hepatic acute phase response; Interleukin 6

Indexed keywords

ACETYLCHOLINE; ACUTE PHASE PROTEIN; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; APOLIPOPROTEIN E; C REACTIVE PROTEIN; CATHEPSIN; CELL ADHESION MOLECULE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; IRBESARTAN; JANUS KINASE; KININ; LIPID; LOSARTAN POTASSIUM; LOW DENSITY LIPOPROTEIN; METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RAMIPRIL; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RENIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR; UNINDEXED DRUG;

ACUTE PHASE RESPONSE; ADIPOCYTE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL; CLINICAL TRIAL; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEEDBACK SYSTEM; GENE; GENE EXPRESSION; HEART INFARCTION; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; LIVER; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ACUTE-PHASE PROTEINS; ANGIOTENSIN II; ANIMALS; ARTERIOSCLEROSIS; CHOLESTEROL, LDL; ENDOTHELIUM, VASCULAR; FEEDBACK, BIOCHEMICAL; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIVER; MACROPHAGES; MONOCYTES; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; SIGNAL TRANSDUCTION;

EID: 0036347258     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000021412.56621.A2     Document Type: Review

References (125)

1. Mechanisms of disease: Atherosclerosis: An inflammatory disease
2. Current concepts of the pathogenesis of the acute coronary syndromes
3. Renin-angiotensin system: Biochemistry and mechanisms of action
4. The renin-angiotensin system
5. Molecular basis of human hypertension: Role of angiotensinogen
6. Angiotensin II and its receptors in the diabetic kidney
7. Molecular and cellular mechanisms of angiotensin II mediated cardiovascular and renal diseases
8. Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis
9. Angiotensin II and atherosclerosis
10. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension
11. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions
12. Effects of captopril on ischemic events after myocardial infarction: Results of the Survival and Ventricular Enlargement trial: SAVE Investigators
13. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
14. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease
15. The angiotensin converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice
16. ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries
17. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit
18. Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice
19. Endothelial dysfunction: From physiology to therapy
20. Angiotensin-converting enzyme inhibitors and insulin sensitivity: Metabolic effects in hypertension, diabetes, and heart failure
21. Ramipril prevents endothelial dysfunction induced by oxidized low-density lipoproteins: A bradykinin-dependent mechanism
22. Effects of quinapril and losartan on insulin sensitivity in genetic hypertensive rats with different metabolic abnormalities
23. Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats
24. Reversing endothelial dysfunction with ACE inhibitors: A new TREND?
25. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme
26. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan
27. Acute and chronic angiotensin-I receptor antagonism reverses endothelial dysfunction in atherosclerosis
28. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia
29. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression and macrophage accumulation in apolipoprotein E deficient mice
30. Attenuation of tissue P-selectin and MCP-1 expression and intimal proliferation by AT(1) receptor blockade in hyperlipidemic rabbits
31. AT1 receptor antagonisms reduced endothelial dysfunction and intimal thickening in atherosclerotic rabbits
32. Acceleration of atherosclerotic lesions in transgenic mice with hypertension by the activated renin-angiotensin system
33. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice
34. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice
35. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells
36. Increased NADH-oxidase mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system
37. Angiotensin II induces gene transcription through cell-type dependent effects on the nuclear factor-κB (NF-κB) transcription factor
38. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor
39. Angiotensin II signaling in vascular smooth muscle
40. Cellular and molecular mechanisms of endothelial cell dysfunction
41. Angiotensin II mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone
42. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: Implications for atherosclerotic plaque stability
43. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells
44. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction
45. NADPH oxidase role in cardiovascular biology and disease
46. Stimulation of a vascular smooth muscle cell NAD(P)H oxidase by thrombin: Evidence that p47(phox) may participate in forming this oxidase in vitro and in vivo
47. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology
48. Cell transformation by the superoxide-generating oxidase Moxl
49. Novel gp91phox homologues in vascular smooth muscle cells: Nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways
50. p47phox is required for atherosclerotic lesion progression in apoE-/- mice
51. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: A possible role for interleukin-6
52. Angiotensin II induces LOX, the human endothelial receptor of oxidized low-density lipoprotein
53. Angiotensin II generation at the cell surface of activated neutrophils: Novel cathepsin G-mediated catalytic activity that is resistant to inhibition
54. Angiotensin II stimulates endothelial vascular cell adhesion molecule-I via NF-κB activation induced by intracellular oxidative stress
55. Angiotensin II stimulates intercellular adhesion molecule-I (ICAM-1) expression by human vascular endothelial cells and increases soluble ICAM-1 release in vivo
56. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis
57. Angiotensin converting enzyme inhibition prevents arterial nuclear factor κB activation, MCP-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis
58. Angiotensin II induces IL-6 transcription in vascular smooth muscle cells through pleiotropic activation of NF-κB transcription factors
59. Angiotensin induces inflammatory activation of human vascular smooth muscle cells
60. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice
61. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis
62. Platelet derived IL-1 induces cytokine production, but not proliferation, of human vascular smooth muscle cells
63. Interleukin-6 stimulates growth of vascular smooth muscle cells in a PDGF-dependent manner
64. Irbesaratan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis
65. Angiotensinogen gene activation by AII is mediated by the Rel A (NF-κB p65) transcription factor: One mechanism for the renin angiotensin system (RAS) positive feedback loop in hepatocytes
66. Identification of NF-κB dependent gene networks in respiratory syncytial virus-infected cells
67. NF-kappaB: Pivotal mediator or innocent bystander in atherogenesis?
68. Activated transcription factor nuclear factor-κB is present in the atherosclerotic lesion
69. Elevated plasma interleukin-6 levels inpatients with acute myocardial infarction
70. Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events
71. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
72. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
73. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
74. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
75. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
76. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
77. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
78. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Results from the cardiovascular health and the rural health promotion project
79. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially health middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausberg Cohort Study, 1984 to 1992
80. Infections, inflammation, and the risk of coronary heart disease
81. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
82. C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men
83. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
84. Acute-phase proteins and other systemic responses to inflammation
85. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat
86. Transcriptional control mechanisms of fibrinogen gene expression
87. Angiotensinogen gene expression is dependent on STAT3-mediated p300/CBP coactivator recruitment and HAT activity
88. STATs: Signal transducers and activators of transcription
89. Transcription factors NF-IL6 and APRF involved in gp130-mediated signalling pathways
90. Role of STAT1 and STAT3 in inducible expression of the human angiotensinogen gene by interleukin-6
91. Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver
92. Mechanisms for vascular inflammation as a cardiovascular risk factor
93. The p300/CBP family: Integrating signals with transcription factors and chromatin
94. The CBP coactivator is a histone acetyltransferase
95. Angiotensinogen gene is expressed and differentially regulated in multiple tissues of the rat
96. Cellular localization of angiotensinogen gene expression in brown adipose tissue and mesentery: Quantification of messenger ribonucleic acid abundance using hybridization in situ
97. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation
98. Mechanisms for inducible control of angiotensinogen gene transcription
99. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis
100. Human C-reactive protein: Expression, structure, and function
101. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs
102. Direct proinflammatory effect of C-reactive protein on human endothelial cells
103. Amyloid protein SAA is associated with high density lipoprotein from human serum
104. Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells
105. Molecular genetics of human hypertension: Role of angiotensinogen
106. Relation between blood pressure and renin, renin substrate, AII, aldosterone and urinary sodium and potassium in 574 ambulatory subjects
107. Measurement of plasma-renin substrate by radioimmunoassay of angiotensin, I: Concentration in syndromes associated with steroid excess
108. Genetic control of blood pressure and the angiotensinogen locus
109. Chimeric renin-angiotensin system demonstrates sustained increase in blood pressure of transgenic mice carrying both human renin and human angiotensinogen genes
110. Linkage of the angiotensinogen gene to essential hypertension
111. Angiotensinogen T235 expression is elevated in decidual spiral arteries
112. A molecular variant of angiotensinogen associated with preeclampsia
113. An inducible 50-kilodalton NF kappa B-like protein and a constitutive protein both bind the acute-phase response element of the angiotensinogen gene
114. Acute phase responses of plasma angiotensinogen and T-kininogen in rats
115. Angiotensinogen is an acute-phase protein in man
116. Circulating and tissue angiotensin systems
117. A comparison of the substrate specificities of cathepsin D and pseudorenin
118. Renin release by endothelial cells in culture
119. Proteolytic degradation of low density lipoproteins by arterial smooth muscle cells: The role of individual cathepsins
120. The intracellular distribution of cathepsins and other acid hydrolases in mouse peritoneal macrophages
121. Multiple determinants for the high substrate specificity of an angiotensin II-forming chymase from the human heart
122. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease
123. Chemistry of a human monocyte-derived cell line (U937): Identification of the angiotensin I-converting activity as leukocyte cathepsin G
124. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability
125. Regulation of the angiotensin AT1 receptor expression by hypercholesterolemia